Humacyte Inc (HUMA)

$7.37

-0.11

(-1.47%)

Market is closed - opens 7 PM, 04 Jun 2024

Performance

  • $7.12
    $7.60
    $7.37
    downward going graph

    3.39%

    Downside

    Day's Volatility :6.32%

    Upside

    3.03%

    downward going graph
  • $1.96
    $9.97
    $7.37
    downward going graph

    73.41%

    Downside

    52 Weeks Volatility :80.34%

    Upside

    26.08%

    downward going graph

Returns

PeriodHumacyte Inc
3 Months
108.78%
6 Months
182.38%
1 Year
97.59%
3 Years
104.72%

Highlights

Market Capitalization
890.7M
Book Value
$0.22
Earnings Per Share (EPS)
-1.0
Wall Street Target Price
8.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-36.66%
Return On Equity TTM
-195.68%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
-100.0%
Gross Profit TTM
1.6M
EBITDA
-93.6M
Diluted Eps TTM
-1.0
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.99
EPS Estimate Next Year
-0.82
EPS Estimate Current Quarter
-0.22
EPS Estimate Next Quarter
-0.23

Analyst Recommendation

Buy
    83%Buy
    16%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Humacyte Inc(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
11
11
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 8.55%

Current $7.37
Target $8.00

Technicals Summary

Sell

Neutral

Buy

Humacyte Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin

Institutional Holdings

  • BlackRock Inc

    4.02%
  • Vanguard Group Inc

    3.38%
  • Sio Capital Management, LLC

    1.68%
  • Geode Capital Management, LLC

    1.13%
  • State Street Corporation

    1.02%
  • Prescott Investors Inc

    0.48%

Company Information

biotechnology company

Organization
Humacyte Inc
Employees
183
CEO
Dr. Laura E. Niklason M.D., Ph.D.
Industry
Healthcare

FAQs